European Academy of Dermatology and Venereology (EADV) 31st Congress

Skin biomarkers predict AD risk, severity in newborns

Elvira Manzano, 20221027000000

Predicting which newborn will go on to develop atopic dermatitis (AD) and how severe it will be is now feasible, according to the BABY* study.

Ruxolitinib improves repigmentation in vitiligo through 52 weeks

Elaine Soliven, 20221021000000

Long-term use of ruxolitinib cream continued to improve facial and total body repigmentation in patients with nonsegmental vitiligo from 24 to 52 weeks, according to an updated pooled analysis of the phase III TRuE-V1* and TRuE-V2** studies presented at EADV 2022.

Dupilumab reduces itch, improves skin lesions in prurigo nodularis

Elvira Manzano, 20221020000000

Dupilumab improves itch response and skin lesions in patients with prurigo nodularis (PN) inadequately controlled with prior therapies in the LIBERTY-PN PRIME trial.

Lebrikizumab efficacy in atopic dermatitis maintained at 1 year

Roshini Claire Anthony, 20221012180001

Maintenance lebrikizumab monotherapy appears to improve outcomes in patients with moderate-to-severe atopic dermatitis (AD), according to results of the phase III ADvocate1 and ADvocate2 trials.

Ligelizumab safe, effective in patients with chronic spontaneous urticaria

Elaine Soliven, 20221006000000

Ligelizumab, a next-generation anti-IgE antibody, is safe and effective in treating patients with H₁-antihistamine (H₁-AH) refractory chronic spontaneous urticaria (CSU), according to two phase III studies presented at EADV 2022.

Deucravacitinib bestows benefits in Asian patients with plaque psoriasis

Roshini Claire Anthony, 20221004180001

The benefit of deucravacitinib in moderate to severe plaque psoriasis was demonstrated in a population of Asian patients, according to results of the phase III POETYK PSO-3 trial.

Rocatinlimab a new treatment option for head and neck AD?

Audrey Abella, 20220923100000

Rocatinlimab improved disease severity in patients with moderate-to-severe head and neck atopic dermatitis (H&N AD), a post hoc analysis of a phase IIb trial has shown.

ALLEGRO-LT shows long-term benefit of ritlecitinib for alopecia areata

Audrey Abella, 20220921100000

In the interim analysis of the ongoing phase III ALLEGRO-LT trial, the investigational oral JAK3*/TEC inhibitor ritlecitinib demonstrated long-term safety and remarkable scalp hair regrowth in adults and adolescents with alopecia areata (AA).

Roflumilast shows treatment potential for seborrheic dermatitis

Audrey Abella, 20220915100000

In the phase III STRATUM* trial, the investigational PDE4** inhibitor roflumilast improved multiple symptoms of moderate-to-severe seborrheic dermatitis (SD).